Streetbeat News

ALLR

Allarity Therapeutics, Inc.

https://www.allarity.com

Industry

Biotechnology

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.

Open

1.40

Mkt cap

1.9M

Volume

365K

High

1.40

P/E Ratio

-0.13

52-wk high

666.00

Low

1.27

Div yield

N/A

52-wk low

1.26

In Monday's pre-market session, several healthcare stocks showed significant movement. Soligenix, Longeveron, Cartesian Therapeutics, Biomerica, Allarity Therapeutics, and Envoy Medical were among the gainers, with Soligenix leading by a 95.1% increase. On the downside, Marinus Pharma, TRACON Pharma, Neumora Therapeutics, PaxMedica, Alterity Therapeutics, and SINTX Techs faced declines, with Marinus Pharma dropping by 74.5%. Biomerica's rise was attributed to its Q3 earnings release.

Portfolio Pulse from Benzinga Insights

April 15, 2024 | 12:07 pm

Medical Properties Trust, Inc. (MPW) shares surged 13.1% in pre-market trading after selling its majority interest in Utah Hospitals. Other stocks also showed significant movement in pre-market trading, with notable gainers including Allarity Therapeutics, Inc. (ALLR), Longeveron Inc. (LGVN), and Piedmont Lithium Inc. (PLL), among others. Conversely, several stocks experienced declines, such as AudioEye, Inc. (AEYE), NextPlat Corp (NXPL), and Polestar Automotive Holding Uk Plc (PSNY), driven by various company-specific news and analyst actions.

Portfolio Pulse from Avi Kapoor

April 15, 2024 | 9:45 am

In Friday's after-market session, several healthcare stocks showed notable movements. Qilian Intl Hldg Gr (QLI) led the gainers with a 50.4% increase, while PaxMedica (PXMD) experienced the largest decline among the losers, dropping 8%. Other notable movers included Allarity Therapeutics (ALLR) and Cormedix (CRMD) with significant gains, and OncoCyte (OCX) which declined following its Q4 earnings release.

Portfolio Pulse from Benzinga Insights

April 12, 2024 | 8:31 pm

JPMorgan Chase & Co. shares fell by 5.1% despite beating first-quarter earnings and revenue expectations, with other stocks experiencing significant movements in Friday's mid-day session. Notable gainers include PaxMedica, EZGO Technologies, and Allarity Therapeutics, among others, with various reasons for their stock movements. Conversely, several companies faced declines, such as Motus GI Holdings, Lixiang Education, and Monogram Orthopaedics, each with specific challenges impacting their stock prices.

Portfolio Pulse from Avi Kapoor

April 12, 2024 | 6:47 pm

Allarity Therapeutics Inc has filed a prospectus supplement with the SEC to increase the offering price of its common stock from $2.35 million to $3.2 million.

Portfolio Pulse from Benzinga Newsdesk

April 12, 2024 | 6:27 pm

In Friday's intraday session, several healthcare stocks experienced significant movements. PaxMedica (PXMD) led the gainers with a 110.9% increase, while Motus GI Holdings (MOTS) saw the largest decline at 39%. Other notable movers include Q32 Bio (QTTB), Cyclacel Pharmaceuticals (CYCCP), and Rani Therapeutics Holdings (RANI) among the gainers, and Monogram Orthopaedics (MGRM) and BioSig Technologies (BSGM) among the losers.

Portfolio Pulse from Benzinga Insights

April 12, 2024 | 4:31 pm

In Friday's pre-market session, several healthcare stocks showed significant movement. PaxMedica led the gainers with a 104.2% increase, while Motus GI Holdings experienced the largest drop among the losers, falling 26.1%. The movements reflect notable volatility in the healthcare sector, with companies ranging from biotech to pharmaceuticals experiencing shifts in their stock prices.

Portfolio Pulse from Benzinga Insights

April 12, 2024 | 12:09 pm

NextPlat Corp (NASDAQ:NXPL) shares surged approximately 30% in pre-market trading after announcing a 222% year-over-year increase in consolidated 2023 revenues, reaching $37.8 million. Other stocks also showed significant movement in pre-market trading, with notable gainers including Allarity Therapeutics, PaxMedica, OncoCyte Corporation, and Zapata Computing Holdings, among others. Conversely, several stocks experienced declines, such as Motus GI Holdings, Rent the Runway, and Kazia Therapeutics, driven by various company-specific news and market reactions.

Portfolio Pulse from Avi Kapoor

April 12, 2024 | 9:32 am

Allarity Therapeutics has filed a prospectus supplement with the SEC to increase the offering price of its common stock from $1.4 million to $2.4 million. This move indicates the company's intention to raise more capital through its stock offering.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 5:42 pm

Rallybio Corporation shares surged 77.9% in pre-market trading following a collaboration announcement with Johnson & Johnson on therapeutics for pregnant individuals at risk of FNAIT. Other stocks also showed significant movement in pre-market trading, with notable gainers including Rent the Runway, Alpine Immune Sciences, and TuanChe Limited, among others. Conversely, Aptevo Therapeutics and Acorda Therapeutics led the pre-market losers, with significant drops due to a pipeline update and bankruptcy proceedings, respectively.

Portfolio Pulse from Avi Kapoor

April 11, 2024 | 10:14 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.